N. Palma

发表

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

Roland L Dunbrack, Roland L. Dunbrack, Yan Zhou, 2015, European urology.

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

D. Lipson, V. Miller, Siraj M. Ali, 2014, Case Reports in Oncology.

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.

Siraj M. Ali, S. Pal, N. Palma, 2015, European urology.

Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

R. Yelensky, V. Miller, G. Frampton, 2015, Blood Cancer Journal.

Association of PIK3CA mutation with response (ExRx) to cetuximab (C) in metastatic (met) triple-negative breast cancer (TNBC).

C. Horak, N. Palma, Kai Wang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

P. Stephens, V. Miller, D. Khaira, 2015, Breast Cancer Research and Treatment.

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

P. Stephens, R. Yelensky, D. Lipson, 2015, The oncologist.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

P. Stephens, R. Yelensky, S. Ou, 2015, The oncologist.

Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies

V. Miller, Y. Shyr, A. Greenplate, 2018, JCO precision oncology.

Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.

P. Stephens, R. Yelensky, E. V. Van Allen, 2016, European urology.

Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.

P. Stephens, V. Miller, Siraj M. Ali, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

Howard Kaufman, Shridar Ganesan, Joseph R. Bertino, 2016, The oncologist.

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.

James X. Sun, R. Yelensky, D. Lipson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

P. Stephens, R. Yelensky, D. Lipson, 2016, Cancer.

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*

Michael L. Gatza, Alissa M. Weaver, C. Perou, 2015, Molecular & Cellular Proteomics.

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine

R. Yelensky, J. O’Shaughnessy, J. Pippen, 2015, Cancer medicine.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

S. Boorjian, E. Plimack, R. Uzzo, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy.

G. Frampton, Siraj M. Ali, N. Palma, 2014 .

Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.

R. Yelensky, S. Ou, D. Lipson, 2014 .

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

P. Stephens, R. Yelensky, D. Lipson, 2016, The oncologist.

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.

Ten-year results of chemoradiation for anal cancer: focus on late morbidity.

N. Palma, M. John, M. Flam, 1996, International journal of radiation oncology, biology, physics.

Targeting the Microbiome With KB109 in Outpatients with Mild to Moderate COVID-19 Reduced Medically Attended Acute Care Visits and Improved Symptom Duration in Patients With Comorbidities

N. Palma, K. Knobil, M. Wingertzahn, 2021, medRxiv.

Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive bladder cancer (MIBC).

Roland L. Dunbrack, R. Yelensky, E. Plimack, 2014 .

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

James X. Sun, Chang S. Chan, A. Vazquez, 2016, The oncologist.

319 Genomic profiling of uterine leiomyosarcomas reveal frequent alterations in Akt/mammalian target of rapamycin (mTOR) pathway genes and other actionable genomic abnormalities linked to targeted therapies

V. Miller, Siraj M. Ali, J. Elvin, 2014 .

Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples.

R. Yelensky, D. Lipson, V. Miller, 2013 .

Comprehensive genomic profiling of anal squamous cell carcinoma to reveal frequency of clinically relevant genomic alterations in the PI3K/mTOR pathway.

James X. Sun, P. Stephens, R. Yelensky, 2015 .

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib

V. Miller, R. Erlich, Siraj M. Ali, 2014, Case Reports in Oncology.

Unique genomic features in adolescent and young adult, as compared to older adult, non‐Hodgkin lymphoma and potential therapeutic targets

P. Stephens, R. Yelensky, D. Lipson, 2017, British journal of haematology.